S.A. VLADIMIROV, M.S. ELISEEV

Nasonova Research Institute of Rheumatology, 34a Kashirskoуe highway, Moscow, Russian Federation, 115522

Vladimirov S.A, Cand. Med. Sc., Research scientist of the laboratory of microcrystalline arthritis, tel. (499) 614-44-54, e-mail: ser_vlad@mail.ru

Eliseev M.S, Cand. Med. Sc., Head of the laboratory of microcrystalline arthritis, tel. (499) 614-00-36, e-mail: elicmax@rambler.ru

One of the problems related to successful treatment of gout is the increased risk of acute arthritis in the first months after initiation of urate-lowering therapy. Increasing the frequency of exacerbations arthritis may occur independently of the choice of urate-lowering therapy. The article aims to raise awareness about the importance of prevention of acute gouty arthritis at the initiation of urate-lowering therapy and to summarize the existing clinical data relating to the efficacy and safety of drugs which are currently in use, and new treatment methods being studied.

Key words: gout, prevention, urate-lowering therapy.

REFERENCES

1. Barskova V.G., Mukagova M.V., Severinova M.V., Eliseev M.S., Chikalenkova N.A. Diagnosis of gout. Sibirskiy meditsinskiy zhurnal, 2012, no. 5, pp. 132-135 (in Russ.).
2. Eliseev M.S., Vladimirov S.A., Nasonov E.L. The Frequency of Calcium Pyrophosphate Deposition Disease in Patients with Acute. Ann. Rheum. Dis., 2014, 73(Suppl. 2), rr. 781-782.
3. Silva L., Miguel E.D., Peiteado D., Villalba A., Mola M., Pinto J. et al. Compliance in gout patients. Acta Reumatol. Port., 2010, vol. 35(5), rr. 466-74.
4. Eliseev M.S. Treatment of gout: it is important to remember to avoid errors. Doktor. Ru, 2013, vol. 2(80), pp. 63-69 (in Russ.).
5. Borstad G.C., Bryant L.R., Abel M.P., Scroggie D.A., Harris M.D., Alloway J.A. Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis. J. Rheumatol., 2004, vol. 31(12), rr. 2429-32.
6. Sarawate C.A., Patel P.A., Schumacher H.R., Yang W., Brewer K.K., Bakst A.W. Serum urate levels and gout flares: Analysis from managed care data. J. Clin. Rheumatol., 2006, vol. 12(2), rr. 61-65.
7. Neogi T. Clinical practice. Gout. N. Engl. J. Med., 2011, vol. 364, rr. 443-52.
8. Zhang W., Doherty M., Bardin T., Pascual E., Barskova V., Conaghan P. et al. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for international clinical studies including therapeutics (ESCISIT). Ann. Rheum. Dis., 2006, vol. 65, rr. 1312-24.
9. Terkeltaub R.A. Colchicine Update: 2008. Semin. Arthr. Rheum., 2009, vol. 38(6), rr. 411-9.
10. Imazio M. Colchicine for pericarditis. Trends in cardio vascular medicine, 2015, vol. 25, rr. 129-136.
11. Yu T.F., Gutman A.B. Efficacy of colchicine prophylaxis in gout. Prevention of recurrent gouty arthritis over a mean period of five years in 208 gouty subjects. Ann. Intern. Med., 1961, vol. 55, rr. 179-92.
12. Yang L.P. Oral colchicine (Colcrys®) in the treatment and prophylaxis of gout: Profile report. Drugs Aging, 2010, vol. 27(10), rr. 855-7.
13. Gutman AB. Treatment of primary gout: The present status. Arthritis Rheum., 1965, vol. 8, rr. 911-20.
14. Paulus H.E., Schlosstein L.H., Godfrey R.G. et al. Prophylactic colchicine therapy of intercritical gout a placebo-controlled study of probenecid-treated patients. Arthritis Rheum., 1974, vol. 17(5), rr. 609-14.
15. Wortmann R.L., Macdonald P.A., Hunt B., Jackson R.L. Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: Analysis of data from three phase III trials. Clin. Ther., 2010, vol. 32(14), rr. 2386-97.
16. Kuritzky L., Panchal R. Gout: Nonsteroidal anti-inflammatory drugs and colchicine to prevent painful flares during early uratelowering therapy. J. Pain Palliat Care Pharmacother., 2010, vol. 24(4), rr. 397-401.
17. Singh J., Yang S., Foster J. The risk of aplastic anemia and pancytopenia with colchicine: a retrospective study of integrated health system database. Art. Rheum., 2014, vol. 66; 11(Suppl.), p.20.
18. Stanley M.W., Taurog J.D., Snover D.C. Fatal colchicine toxicity: report of a case. Clin Exp Rheumatol, 1984, vol. 2(2), rr. 167-71.
19. Crittenden D.B., Kimmel J.N., Pike V.C. et al. Colchicine and risk of acute cardiovascular (CV) events among gout patients: the New York Department of veterans affairs retrospective cohort study. Art. Rheum, 2014, vol. 66; 11(Suppl.), S65.
20. Nidorf S.M., Eikelboom J.W., Budgeon C.A., Thompson P.L. Low-dose colchicine for secondary prevention of cardiovascular disease. JACC, 2013, vol. 61, rr. 404-410.
21. Doghramji P.P. Managing your patient with gout: A review of treatment options. Postgrad Med, 2011, vol. 123(3), rr. 56-71.
22. Becker M.A., Schumacher H.R., Espinoza L.R., Wells A.F., MacDonald P., Lloyd E. et al. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: The confirms trial. Arthritis Res. Ther, 2010, vol. 12(2), rr. 63.
23. Schumacher H.R.Jr., Becker M.A., Wortmann R.L., Macdonald P.A., Hunt B., Streit J. et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: A 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum, 2008, vol. 59(11), rr. 1540-8.
24. Pham K., Hirschberg R. Global safety of coxibs and NSAIDs. Curr. Top Med. Chem, 2005, vol. 5(5), rr. 465-73.
25. Eliseeva M.E., Eliseev M.S., Tsurko V.V. Risk factors for gout in elderly persons (preliminary data). Doktor.Ru, 2011, vol. 7(66), pp. 42-44 (in Russ.).
26. American College of Rheumatology, Ad Hoc Group on Use of Selective and American College of Rheumatology Ad Hoc Group on Use of Selective and Nonselective Nonsteroidal Antiinflammatory Drugs. Recommendations for use of selective and nonselective nonsteroidal anti-inflammatory drugs: An American College of Rheumatology white paper. Arthritis Rheum, 2008, vol. 59(8), rr. 1058-73.
27. Trelle S., Reichenbach S., Wandel S., Hildebrand P., Tschannen B., Villiger P.M. et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: Network meta-analysis. BMJ, 2011, vol. 342, rr. 70-86.
28. Munar M.Y., Singh H. Drug dosing adjustments in patients with chronic kidney disease. Am. Fam. Physician, 2007, vol. 75(10), rr. 1487-96.
29. Janssens H.J., Lucassen P.L., Van de Laar F.A., Janssen M., Van de Lisdonk E.H. Systemic corticosteroids for acute gout. Cochrane Database Syst. Rev, 2008 Apr 16(2), CD005521.
30. So A., De Meulemeester M., Pikhlak A., Yucel A.E., Richard D., Murphy V. et al. Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: Results of a multicenter, phase II, dose-ranging study. Arthritis Rheum, 2010, vol. 62(10), rr. 3064-76.
31. So A., De Smedt T., Revaz S., Tschopp J. A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res. Ther, 2007, vol. 9(2), r. 28.
32. Terkeltaub R., Sundy J.S., Schumacher H.R., Murphy F., Bookbinder S., Biedermann S. et al. The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: Results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study. Ann. Rheum. Dis, 2009, vol. 68, rr. 1613-7.
33. Dinarello C.A. An expanding role for interleukin-1 blockade from gout to cancer. Mol. Med, 2014, Dec. 16; 20, suppl. 1, rr. 43-58.
34. Schlesinger N., Mysler E., Lin H.Y., De Meulemeester M., Rovensky J., Arulmani U. et al. Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: Results of a double-blind, randomised study. Ann. Rheum. Dis, 2011, vol. 70(7), rr. 1264-71.
35. Schlesinger N., Alten R.E., Bardin T. Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled,double-blind trials and their initial extensions. Annals of Rheumatic Diseases, 2012, vol. 71(11), rr. 1839-1848.
36. Eliseev M.S., Zhelyabina O.V., Barskova V.G., Nasonov E.L. Experience of inhibitor interleykina1β kanakinumaba in patients with chronic gout tofusnoy. Nauchno-prakticheskiy revmatizm, 2014, vol. 1, pp. 99-101 (in Russ.).
37. Noe A., Howard C., Thuren T., Taylor A., Skerjanec A. Pharmacokinetic and Pharmacodynamic Characteristics of Single-dose Canakinumab in Patients With Type 2 Diabetes Mellitus. Clin. Ther, 2014, vol. 36(11), rr. 1625-37.
38. Ridker P.M. Closing the loop on inflammation and atherothrombosis: why perform the CIRT and CANTOS trials? Trans Am. Clin. Climatol. Assoc, 2013, vol. 124, rr. 174-90.
39. ClinicalTrials.gov, Identifier: NCT01712204.
40. Schumacher H.R.Jr., Sundy J.S., Terkeltaub R., Knapp H.R., Mellis S.J., Stahl N. et al. Rilonacept (IL-1 trap) in the prevention of acute gout flares during initiation of urate-lowering therapy: Results of a phase 2 clinical trial. Arthritis Rheum, 2012, vol. 64(3), rr. 876-884.
41. Mitha E., Schumacher H.R., Fouche L. et al. Rilonacept for gout flare prevention during initiation of uric acid-lowering therapy: results from the PRESURGE-2 international, phase 3, randomized, placebo-controlled trial. Rheumatology, 2013, vol. 7(52), rr. 1285-1292.
42. Richette P., Doherty M., Pascual E., Barskova V. et al. Updated Eular Evidence-Based Recommendations for the Management of Gout. Ann. Rheum. Dis, 2014, vol. 73: suppl. 2, r. 783.
43. Singh J.A., Hodges J.S., Asch S.M. Opportunities for improving medication use and monitoring in gout. Ann. Rheum. Dis, 2009, vol. 68(8), rr. 1265-70.